Why the study?
Moderate-to-severe tricuspid regurgitation contributes significantly to heart failure hospitalizations and traditional treatments have several limitations, prompting evaluation of transcatheter edge-to-edge repair.
Does transcatheter edge-to-edge repair (TEER) improve device performance and clinical outcomes in symptomatic patients with severe tricuspid regurgitation?
Does transcatheter edge-to-edge repair (TEER) improve device performance and clinical outcomes in symptomatic patients with severe tricuspid regurgitation?
Tricuspid TEER with the TriClip system provides durable reduction in tricuspid regurgitation and improves functional status and right ventricular remodeling at 1 year in patients with severe symptomatic TR.
TEER may improve 1-year outcomes in severe symptomatic TR; supports randomized trials before practice change.
AIMS: Tricuspid regurgitation affects 7% of the population, with moderate-to-severe tricuspid regurgitation contributing to up to 12% of heart failure-related hospitalizations. Traditional treatments have several limitations, prompting the exploration of innovative interventions. Our study aims to investigate the efficacy and clinical outcomes following transcatheter edge-to-edge repair (TEER) in patients with severe, symptomatic tricuspid regurgitation through a 1-year follow-up. METHODS: The TR-Interventional study (TRIS) is a prospective, single-arm study conducted at the Fondazione Policlinico Universitario Campus Bio-Medico. From March 2021 to December 2023, we enrolled 44 symptomatic patients with at least severe tricuspid regurgitation referred for tricuspid TEER with the TriClip System. RESULTS: The study cohort had a mean age of 78.3 ± 7 years with a median TRISCORE 5.4% (interquartile range 3.5-9.0). Significant reduction in tricuspid regurgitation grade occurred immediately after the procedure with durable results at 30 days and 1-year follow-up (P < 0.001). The primary efficacy endpoint, which assesses the successful implantation and performance of the device at 30 days, was attained in 82.9% of patients. The secondary efficacy endpoint, evaluating the stability of tricuspid regurgitation reduction at 12 months, was achieved in 82.3% of patients. The NYHA Functional Class and KCCQ scores significantly improved from baseline to 1 year (P < 0.05; P < 0.0001). Echocardiographic assessments reveal sustained positive right ventricle remodeling throughout the 1-year follow-up period. CONCLUSION: Evidence from the TRIS study confirms that tricuspid TEER is a valuable and effective therapeutic option in contemporary practice. The lasting reduction in tricuspid regurgitation at 1 year is associated with sustained clinical benefits and reverse structural remodeling of the right ventricle.
No takes yet. Share an insight, caveat, or question.
Carpenito et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: